Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Current Leases came in at $45.9 million in Q2 2026, little changed YoY from $46.1 million in Q2 2025, and up 0.6% on a QoQ basis from $45.7 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 8 years of Current Leases data on file, last reported at $45.9 million in Q2 2026.
- Quarterly Current Leases changed 0.36% year-over-year to $45.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $45.9 million (changed 0.36% YoY) and the FY2025 annual result came in at $45.5 million, up 8.67% from the prior year.
- Current Leases rose to $45.9 million in Q2 2026, from $45.7 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $46.1 million in Q2 2025 to a low of $41.2 million in Q2 2022.
- A 5-year average of $43.1 million and a median of $42.0 million in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases retreated 3.21% — and 2025, when it climbed 10.66%.
- Tracing ALNY's Current Leases over 5 years: stood at $42.0 million in 2022, then fell by 1.09% to $41.5 million in 2023, then rose by 0.91% to $41.9 million in 2024, then climbed by 8.67% to $45.5 million in 2025, then gained by 0.91% to $45.9 million in 2026.
- The last three Current Leases figures came in at $45.9 million (Q2 2026), $45.7 million (Q1 2026), and $45.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.93 Mn |
| Mar 31, 2026 | 45.66 Mn |
| Dec 31, 2025 | 45.52 Mn |
| Sep 30, 2025 | 44.76 Mn |
| Jun 30, 2025 | 46.10 Mn |
| Mar 31, 2025 | 46.01 Mn |
| Dec 31, 2024 | 41.89 Mn |
| Sep 30, 2024 | 42.14 Mn |
| Jun 30, 2024 | 41.66 Mn |
| Mar 31, 2024 | 41.67 Mn |
| Dec 31, 2023 | 41.51 Mn |
| Sep 30, 2023 | 41.52 Mn |
| Jun 30, 2023 | 42.07 Mn |
| Mar 31, 2023 | 43.06 Mn |
| Dec 31, 2022 | 41.97 Mn |
| Sep 30, 2022 | 41.58 Mn |
| Jun 30, 2022 | 41.24 Mn |
| Mar 31, 2022 | 41.29 Mn |
| Dec 31, 2021 | 40.55 Mn |
| Sep 30, 2021 | 40.61 Mn |